LIXTE Files 8-K on Common Stock & Warrants Activity
Ticker: LIXT · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1335105
Sentiment: neutral
Topics: corporate-action, warrants, common-stock
Related Tickers: LIXT
TL;DR
**LIXTE filed an 8-K on Feb 27, hinting at common stock and warrant activity, but specific details are missing.**
AI Summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K on February 27, 2024, reporting under "Other Events" and "Financial Statements and Exhibits." The filing indicates activity related to common stock and warrants as of that date, though specific transaction details or dollar amounts are not provided in the excerpt.
Why It Matters
This filing signals potential corporate actions related to LIXTE's capital structure, specifically common stock and warrants, which could impact shareholder value, though the specific nature of the event is not detailed in the provided text.
Risk Assessment
Risk Level: medium — The filing mentions "Other Events" and capital instruments (common stock, warrants) without specific details, creating uncertainty about potential impacts on the company or investors.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — filer
- February 27, 2024 (date) — report date
- 001-39717 (identifier) — SEC File Number
- 0001335105 (identifier) — Central Index Key (CIK)
FAQ
What company filed this 8-K?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed this 8-K.
What was the date of the earliest event reported in this filing?
The earliest event reported was on February 27, 2024.
Under which item categories was this 8-K filed?
This 8-K was filed under "Other Events" and "Financial Statements and Exhibits."
What specific financial instruments are mentioned in the XBRL data for this date?
The XBRL data mentions Common Stock and Warrants as of February 27, 2024.
What is the registrant's telephone number?
The registrant's telephone number is (631) 830-7092.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 12.7 · Accepted 2024-02-27 16:59:41
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 14KB
- 0001493152-24-007997.txt ( ) — 261KB
- lixt-20240227.xsd (EX-101.SCH) — 3KB
- lixt-20240227_def.xml (EX-101.DEF) — 26KB
- lixt-20240227_lab.xml (EX-101.LAB) — 36KB
- lixt-20240227_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The Company is filing as part of this report the exhibits listed on the accompanying Index to Exhibits, which information is incorporated herein by reference. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 27, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan President and Chief Executive Officer 3 INDEX TO EXHIBITS Exhibit No. Description 99.1 Press release announcing the presentation of Dr. Ren Bernards at the Joint Conference of European and American Associations for Cancer Research 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 4